Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 18/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 10/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995626 | 1.00 | PTGER4 (0.49) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL5733485 | 0.87 | PTGER4 (0.48) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL5733480 | 0.87 | PTGER4 (0.48) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL10969201 | 0.84 | PTGER4 (0.47) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL6712960 | 0.82 | PTGER4 (0.49) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL6712964 | 0.82 | PTGER4 (0.49) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL4994022 | 0.82 | PTGER4 (0.47) | PTGER4PTGER3PTGER2USP2ALDH1A1 | |
| SCHEMBL4994025 | 0.82 | PTGER4 (0.47) | PTGER4PTGER3PTGER2USP2ALDH1A1 | |
| SCHEMBL10970283 | 0.81 | PTGER4 (0.62) | PTGER4PTGER3PTGER2KCNH2PTGER1 | |
| SCHEMBL18831938 | 0.81 | PTGER4 (0.62) | PTGER4PTGER3PTGER2KCNH2PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650414-B1 | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2017-05-16 | — | — | US | disclosed |
| US-9650414-B1 | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2017-05-16 | — | — | US | disclosed |
| US-9611284-B2 | Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2017-04-04 | — | — | US | disclosed |
| US-9611284-B2 | Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2017-04-04 | — | — | US | disclosed |
| US-20130157984-A1 | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, METHODS OF MAKING SAME, AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2013-06-20 | — | — | US | disclosed |
| US-20130157984-A1 | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, METHODS OF MAKING SAME, AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2013-06-20 | — | — | US | disclosed |
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8207223-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207223-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | SYNTEX (U.S.A.) LLC | 2003-06-26 | — | — | US | disclosed |
| WO-2003047513-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| US-6552067-B2 | For therapy of osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| WO-2003008377-A1 | PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | disclosed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| WO-2002042268-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O'KEEFE (US) | 2002-04-04 | — | — | US | disclosed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER2 3/4885 |
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER2 3/4885 |
| US-20130157984-A1 | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, METHODS OF MAKING SAME, AND USES THEREOF | PTGES, PTGFR, PTGIS | PTGER4 14/4885PTGER3 15/4885PTGER2 10/4885 |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER2 3/4885 |
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | PTGER4, FFAR4, PTGER1 | PTGER4 1/4885PTGER3 11/4885PTGER2 15/4885 |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.